BOSTON — OutcomesAI, a healthcare technology company developing AI-driven nursing solutions, announced it has raised $10 million in seed financing led by Santé Ventures. The funding will accelerate the company’s expansion into health systems, virtual care programs, and pharmaceutical partnerships.
OutcomesAI’s platform, Glia, combines AI-powered voice agents with licensed nurses to increase nursing capacity, lower operational costs, and provide patients with faster access to care. Glia’s AI agents manage inbound and outbound patient calls, capture symptoms, schedule visits, and deliver education in multiple languages. Licensed nurses supported by the system handle clinical services such as triage, post-acute follow-ups, and patient support, aided by AI tools for real-time scribing and protocol guidance. The hybrid model is designed to create up to five times more nursing capacity while reducing costs by as much as 50 percent compared to outsourced triage models.
“Healthcare is running out of nursing capacity, and incremental fixes won’t solve it,” said Kuldeep Singh Rajput, Founder and CEO of OutcomesAI. “With OutcomesAI, we’re not replacing nurses — we’re multiplying them. By combining AI voice agents with licensed nursing teams, we give back time to the people at the center of care, reduce burnout, and build a sustainable, scalable model for the future.”
“With a projected shortfall of 13 million nurses by 2030, the industry is desperate for scalable solutions,” said Joe Cunningham, M.D., Founding Managing Director of Santé Ventures. “We invested in OutcomesAI because they are rethinking how nursing capacity can be scaled — not with incremental fixes, but with a model that blends AI with clinical services to deliver measurable impact. We believe this approach has the potential to redefine virtual care and set a new standard for safety, empathy, and efficiency in healthcare.”
The company’s technology aims to address widespread nursing shortages that have strained healthcare systems worldwide. Nurses currently spend the majority of their time on triage, follow-ups, and coordination, with only a fraction devoted to direct patient care. OutcomesAI’s approach is designed to relieve that burden while maintaining quality and patient satisfaction.
The funding will also support the launch of new nursing service lines and the scaling of enterprise partnerships. In 2024, OutcomesAI launched the OutcomesAI Collaboratory, partnering with leading health systems and virtual care providers to validate Glia’s safety, accuracy, and performance. Early findings show significant reductions in nurse workload and increased patient-to-nurse ratios.
The company’s leadership team includes healthcare and technology veterans from Mayo Clinic, Amwell, Philips, Best Buy Health, and Biofourmis. Rajput, who previously founded Biofourmis, brings a track record of building clinically validated AI companies.
As part of the financing, Joe Cunningham, M.D., Linda Finkel, Dennis McWilliams, and Kevin White, Ph.D., will join OutcomesAI’s board of directors alongside Rajput.
